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Human papillomavirus (HPV) is the most common sexually transmitted disease (STD) in 
the United States (Seto, Marra, Raymakers, & Marra, 2012).  A literature review was 
conducted to investigate the barriers to vaccine uptake in the male population.  Barriers 
were categorized into three main categories including lack of education, perceived fears, 
and inaccessibility.  The review of literature revealed that education is critical in breaking 




   
 As a health care provider, it is important to fully understand the ailments that frequently 
affect the community in which you practice.  In general, members of the community have 
knowledge of the “larger” common diseases, such as diabetes, cardiovascular disease, and 
cancer.  However, there is minimal public knowledge of the human papillomavirus (HPV), the 
risks for contracting, disease progression, treatment options, and most importantly disease 
prevention.   
 HPV is the most common sexually transmitted disease (STD) in the United States (Seto, 
Marra, Raymakers, & Marra, 2012). The virus has more than 100 strains that have been 
identified and fully sequenced, with more than forty strains being linked to genital mucosal 
infections.  The strains are divided into oncogenic and non-oncogenic categories (Herzog, 
Vallerie, Smith, & Wright, 2008).  Oncogenic strains have been further classified into high risk, 
probable high risk, and low risk subgroups.  HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68, 73, and 82 have all been identified as high risk malignancy strains.  Strains 26, 53, 
and 66 are classified as probable high risk.  Low risk cancer strains include 6, 11, 40, 42, 43, 44, 
54, 61, 70, 72, 81, and CP6108 (Satyprakash, Rosella, Ravanfar, & Mendoza, 2009).  Further 
discussion of the HPV types within this article will focus on the strains contained within the 
quadrivalent and bivalent HPV vaccines, specifically types 6, 11, 16, and 18. 
 According to the Centers for Disease Control and Prevention (CDC) (2011a), nearly 50% 
of all sexually active people will contract HPV in their lifetime.  Therefore, 100% of sexually 
active people are at risk for contracting HPV and developing an HPV related cancer.  Cervical, 
vaginal, vulvar, penile, anal, and oropharyngeal cancers are all linked with HPV.  Cervical 
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cancer is the most common HPV related cancer, with nearly all cases being attributed to HPV 
genotypes 16 and 18 (Garland & Smith, 2010).  CDC (2011a) reports that HPV is the cause of 
about 50% of all vulvar, 65% of vaginal, 35% of penile, 95% of anal, and 60% of oropharyngeal 
cancers.  Due to the severity of this worldwide health problem, Healthy People (HP) 2020 is 
currently developing goals to reduce the rates of HPV through raising awareness among heath 
care providers.   
 Cervical cancer is the leading cause of death of women in developing countries 
(Satyprakash, et. al., 2009).   In 2006 the Food and Drug Administration (FDA) approved a 
Merck manufactured quadrivalent vaccine, called Gardasil®, to be a prophylactic HPV related 
cancer treatment for females between 11 and 26 years of age.  The quadrivalent vaccine contains 
two non-oncogenic (6 & 11) and two oncogenic (16 & 18) strains of HPV.  The non-oncogenic 
strains are credited with causing approximately 90% of genital wart cases (Pomfret, Gagnon, & 
Gilchrist, 2010), and types 16 and 18 are responsible for more than 70% of invasive cervical 
cancers (Garland & Smith, 2010).  Two years later, the FDA broadened its approval for the 
quadrivalent vaccine to include males, ages 13 to 26 (Promfret et al., 2010).  The second 
prophylactic vaccine is Cervarix® which is manufactured and distributed by GlaxkoSmithKline.  
Cervarix® was approved for administration to females between ages 10 and 25 in October of 
2008 (U.S. Food and Drug Administration, 2009).  The bivalent vaccine only contains oncogenic 
types 16 and 18.   
 Overall, both vaccines are reported as being generally well tolerated by participants with 
minimal side effects.  Common side effects of both vaccines include swelling, redness, and pain 
at the injection site (Pomfret et al., 2010).  Vaccine adverse reaction data, reported by the 
Vaccine Adverse Event Reporting System (VAERS), was analyzed by medical professionals to 
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identify relationships linking the quadrivalent vaccine to seriously reported side effects such as 
blood clots, Guillain-Barre Syndrome (GBS), stroke, seizures, and allergic reactions.  There were 
no common causes identified that linked the quadrivalent vaccine with central nervous system 
disorders, blood clots, stroke, or seizures (Pomfret et al., 2010). 
 Studies have shown that both the quadrivalent and the bivalent prophylactic vaccines are 
highly efficacious against cervical cancers caused by HPV subtypes 16 and 18; additionally the 
quadrivalent vaccine is 73% effective in protecting against other anogenital and vaginal lesions 
caused by subtypes 6 and 11 (Pomfret et al., 2010).  Since HPV is the most common STD and 
the cost of sequelae is estimated at $2.9 billion (Mahoney, 2006), it is extremely important to 
increase the uptake of the HPV vaccine in both males and females to reduce the rate of 
prevalence and unnecessary health care costs.   
Campaigns to vaccinate against HPV have faced many barriers since the approval for 
girls in 2006 and for boys in 2008.  Some of these barriers have been identified in the review of 
literature; however the topic is lacking an abundance of studies, especially in males.  Research 
that has been conducted has shown some emerging themes related to the barriers for this 
particular vaccination.  A systematic review of literature was performed to investigate “What are 
the barriers to HPV vaccine administration in males?” 
 
Process of Discovery 
 
 A literature search was performed using CINAHL, MEDLINE, PubMed, and Proquest 
databases.  HPV vaccine, barriers, female, costs, and boys were the keywords used to search for 
articles in all databases.  The keywords were searched in different combinations of AND and OR 
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within each database to broaden the return of articles.  The search was narrowed by limiting to 
only peer reviewed articles between 2007 and 2012.  CINAHL, PubMed, and Proquest returned 
33, 49, and 38 articles respectively using the following combination of key terms: HPV vaccine 
barriers AND boys.  CINAHL returned 49 and MEDLINE returned 6 articles using the following 
combination of key terms: HPV vaccine AND females AND barriers.  Additionally, CINAHL 
and MEDLINE returned 35 and 17 articles respectively using HPV vaccine AND cost as key 
term searches.  The term HPV was used in a MeSH search in MEDLINE in which adverse 
effects, economics, and history were used to broaden results for barriers and 389 articles were 
found.  Only meta-analysis and synthesis of literature articles were retained for further appraisal.  
Articles were selected for review based on relevance to the question “What are the barriers to 
HPV vaccine administration in males?”  The review of literature revealed three common themes: 
lack of education, perceived fears, and inaccessibility.   
 
Review of Literature 
 
When reviewing the literature available, it becomes evident that lack of knowledge in 
most populations is a major issue regarding HPV.  The research that has been conducted with 
males as the target population has identified lack of knowledge as being one of the primary road 
blocks in vaccination efforts (Brewer, Ng, McRee, & Reiter, 2010; Katz, Krieger, & Roberto, 
2011; Friedman & Shepeard, 2007).  A survey conducted by Brewer et al. (2010) showed 41% of 
the participants knew that HPV caused genital warts, 24% knew it caused anal cancer, and 23% 
knew it caused oral cancer. Another study done by Katz et al. (2011) supported the findings of 
the previous study as it found that only 12.1% of the college age male participants believed they 
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could be at risk for contracting HPV even though 80% of those surveyed were sexually active.  
The same study also found a low awareness in regards to the availability of a vaccine to prevent 
HPV, with only 15.8% having any knowledge of the HPV vaccine for preventing cancer and 
11.5% knowing of the vaccine in relation to preventing genital warts (Katz et al., 2011).  A 
similar study cited statistics with only 16% of the male participants having any knowledge of the 
HPV vaccine (Hernandez, Wilkens, Thompson, Shvetsov, Goodman, Ning, & Kaopua, 2010).  
The available research, though not vast in quantity, clearly shows an extremely low familiarity of 
HPV and the risks associated in regards to the male population.  In comparison to girls, the 
vaccination of boys in the United States lags behind significantly.  The CDC states that 
according to the 2011 National Immunization Survey for teens only 1 percent of boys received 
the full 3 recommended doses to complete the series, compared to 35% of their female 
counterparts (“Centers”, 2011).   
As stated, knowledge deficit has clearly been identified as a major barrier in acceptability 
of the HPV vaccine for both males and females.  However, there are several other barriers 
identified in the literature along with lack of knowledge.  Perception of low risk is one of the 
barriers identified in the literature directly related to males.  The research conducted with male 
sampling has shown extremely low concern over acquiring HPV related illnesses (Katz et al., 
2011; Hernandez et al., 2010).  There is some deviation between males who identify as 
heterosexual and those that identify as bisexual/homosexual with the latter being slightly more 
concerned with potential risk and more likely to take preventative measures (Hernandez et al., 
2010).  These findings coincide with lack of knowledge.  It is evident that in a population more 
knowledgeable of HPV there is a more realistic understanding of perceived risks. 
 8 
 
Education of the HPV vaccine has fallen short of delivering complete information to both 
male and female patients, due to the FDA initially only approving the vaccine for girls.  Limited 
studies have been done to evaluate young adults’ knowledge of the HPV vaccine.  Overall, 
studies suggest that females report a higher awareness of HPV and a greater acceptance of the 
HPV vaccine than males (Bynum, Brandt, Friedman, Annang, & Tanner, 2011; Friedman & 
Shepeard, 2007).  These findings are thought to be due to the fact that marketing campaigns 
targeted young women as candidates for the quadrivalent vaccine.  A study performed by Bynum 
et al. (2011) focused on HPV knowledge within in the African American young adult population 
and identified that educational information on the virus would be better received, especially in 
males, through marketing campaigns via the Internet, television, radio, and social networking 
sites rather than through their health care provider (Bynum et al., 2011, Friedman et al., 2007).  
However, compared to talking to their parents studies have shown that young people would 
prefer to talk with their health care provider due to the sensitive nature of this subject (Katz et al., 
2011). 
The HPV vaccine was added to the immunization recommendation list for females and is 
listed as an optional vaccine for males by the Advisory Committee on Immunizations Practices 
(ACIP) (Bartlett & Peterson, 2011; Slomovitz & Bodurka, 2007).  However, the responsibility to 
educate patients and families was left up to health care providers.  According to Bartlett et al 
(2011), parents have reported some knowledge of HPV, its link with cervical cancer, and the 
vaccine; however, many parents reported they were unaware of its link with genital warts or the 
fact that the virus is sexually transmitted.  The majority of parents cited their informational 
sources as media marketing advertisements from sources other than their child’s pediatrician.  
Providers report adequate education and knowledge of the HPV vaccine, but they also report 
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having limited accessibility to work with other providers to increase the vaccine uptake (Bartlett 
et al., 2011).  Most studies felt that all health care providers, including pediatrics, primary care, 
obstetrics and gynecology, and community school nurses, need to become more involved with 
educating the public about the HPV vaccine (Bartlett et al., 2011; Slomovitz et al., 2007).  A 
study done by Slomovitz et al. (2007) showed that only 55% of parents accepted the vaccine for 
their children, but after additional education there was a 20% increase in parents willing to 
vaccinate their sons and/or daughters.  Furthermore, after educating parents on the link with HPV 
and cervical cancer an additional 84% of mothers were willing to vaccinate their daughters 
(Slomovitz et al., 2007).    
Much like the issues with lack of knowledge and perceptions discussed previously, and of 
just as much importance, is that of the parental influence.  Since the vaccine is recommended at a 
young age when the patient would still be considered a minor, the parent’s decision on whether 
his or her child should be vaccinated plays a big role in the efforts to increase uptake.  According 
to the available literature and studies there seems to be much hesitancy on the part of parents 
when it comes to vaccinating their child with the HPV vaccine.  The perceived benefit of the 
vaccine and willingness to vaccinate among parents is moderately low, especially when it comes 
to vaccinating boys where it is below 50% of acceptance among parents.  There were several 
common themes across the sources when it came to the reasoning behind the hesitancy.  Some of 
the major barriers identified included lack of knowledge, cost, religious beliefs, fear of adverse 
effects, and fears of promoting promiscuity (Reiter, McRee, Gottlieb, & Brewer, 2010; Katz, 
Reiter, Heaner, Mack, Ruffin, Post, & Paskett, 2009; Reiter, McRee, Pepper, Chantala, & 
Brewer, 2011).  Again, the issue of education and lack thereof becomes a theme that in order to 
increase vaccination rates would need serious addressing of the public. 
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Although education is very important for both health care providers and the public, one 
study done by Rothman & Rothman (2009) strongly suggests that the original educational 
message for the HPV vaccine emphasized the wrong information.  Merck launched the original 
Gardasil® advertisement in a campaign to protect one less girl from losing her life to cervical 
cancer caused by HPV types 6, 11, 16, and 18.  The national campaign maximized education that 
focused on cancer prevention and minimized education relating the HPV virus to sexual 
transmission.  By minimizing the fact that the virus is sexually transmitted, the populations most 
at risk for contracting HPV have discounted the importance of getting vaccinated (Rothman et 
al., 2009).  Furthermore, marketing minimized the male concerns for HPV because men 
perceived HPV to be less severe for themselves since it was labeled a “women’s disease” 
(Bynum et al., 2011, p. 300).  
The second theme derived from the review of literature was perceived fears of patients 
and parents.  The concept of fear ranged from the dread of the physical pain of the injection to 
the concern of promoting sexual activity at a young age.  In general, adolescents are scared of 
pain, especially pain caused by needles, and currently both vaccines are administered on a three 
dose schedule, which results in three times the pain (Pomfret et al., 2010; Conroy et al., 2009).  
Friedman et al. (2007) showed parents reported fear of the vaccine because it could actually 
increase the rate of STDs due of the possibility of decreasing the rate of condom usage, and they 
thought it could possibly give young people the perception that they were immune to STDs.  
Young adult females expressed fear of receiving the vaccine because it could brand them as 
promiscuous since it protects against a STD (Friedman et al., 2007).  Another study indicated 
that parents were apprehensive about administering the vaccine because they thought it might 
promote riskier sexual behavior earlier in adolescents (Bartlett et al. 2011).   
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Other fears of the vaccine include lack of efficacy and adverse effects as cited by 
Slomvitz et al. (2007).  However, multiple studies have shown both the quadrivalent and bivalent 
vaccines to be well tolerated with minimal side effects (Pomfret et al., 2010; Gorin, Glenn, & 
Perkins, 2011).  Conversely, Friedman et al. (2007) proposed that raising awareness of the 
vaccine itself may stimulate public fear.   This was discovered in the study when there was an 
increase in anxiety and fear noted in participants that had received additional information linking 
HPV with cervical cancer.  Friedman et al. (2007) strongly suggests using caution not to cause 
public distress when trying to promote HPV awareness.  Interestingly, another fear reviled by 
Friedman et al. (2007) showed African Americans still distrust the government.  Reasons listed 
for governmental cynicism were the “Tuskegee Study and… conspiracy theories about 
HIV/AIDS and genocide of the African American people” (Friedman et al., 2007 p. 481). These 
ill feelings toward the government could affect the African American population’s perception of 
HPV information and education. 
Although fear of the vaccine and its stigma are barriers to some, others report 
inaccessibility as the major obstacle.  Cost of the vaccine is a large barrier to inhibit access 
because it affects both providers and patients.  Providers are concerned with expenses of 
purchasing the vaccine, participating in insurance plans, and HPV reimbursement rates.  
Furthermore, it is probably not cost effective for the provider to offer the vaccine if there is not a 
large adolescent population seen in the practice.  Parents also report cost as an inhibitor to 
vaccinating their children for HPV (Bartlett et al., 2011).  There are several vaccine associated 
costs for parents: co-pays, transportation, and possibly the full cost of the vaccine if the 
insurance does not reimburse the provider.  Co-payments can be expensive depending on the 
type of insurance plan carried by the patient.  The vaccine is a three part series and could require 
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a co-payment for each visit, but if the vaccine is not covered by insurance, the patient 
responsibility could cost between $320-$400 (Bartlett et al., 2011; Gorin et al., 2011; Reiter, et 
al., 2010; & Walhart, 2012).  Missed vaccination opportunity is also a barrier, because providers 
missed the opportunity to administer the vaccine to patients seeking treatment for other minor 
illnesses or injuries (Conroy et al. 2009).  The fact that the vaccine is a three part series is also a 
barrier because approximately  
90% of those not vaccinated had either not returned to the physician or had not been 
offered the vaccine, [and] it is likely that many of those intending to receive the HPV 
vaccine simply did not have the opportunity to do so during the follow-up period (Conroy 
et al., 2009, p. 1684).  
Access to health care coverage is an additional financial barrier.  Since younger age 
groups are the target for the majority of vaccinations and insurance coverage is often suboptimal, 
age itself also presents a barrier to receiving the vaccine.  High financial cost is a large barrier to 
inhibit the patient from receiving the vaccine because Walhart (2012) reported that Dahlstrom 
discovered parents were more willing to vaccinate both sons and daughters if the vaccine was 
free.    
 
Synthesis of Related Evidence 
 
 After a thorough review of the literature, three major themes were identified when 
investigating barriers to HPV vaccine administration for adolescent males: lack of education 
(including knowledge deficits), perceived fears, and inaccessibility.  Specific barriers that have 
been identified include lack of knowledge of both providers and the public, high cost of the 
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vaccines, the need for a series of 3 injections, inaccessibility to care, fear of adverse effects, 
parental fear related to giving their children a false sense of security when engaging in sexual 
activity, and the stigma that goes along with sexually transmitted diseases.  It appears that most 
effective means of increasing the HPV vaccine uptake is to improve the providers comfort with 
discussing the STD and vaccine with the patient/parent and identifying all opportunities to 
administer the vaccine.  It is equally as important for providers to refute the myths of the HVP 
vaccine, give sufficient education, and supply easy access to patients/parents to optimize uptake.  
In order to address the lack of knowledge there must be educational efforts from persons 
considered to be experts in the subject, which means it is important for providers to fully 
understand HPV and the risks/benefits of the HPV vaccine to properly educate their patients.   
Essentially we found similar barriers to vaccine administration between male and female 
patients.  Even though female patients were more aware of HPV, both sexes reported knowledge 
deficits, fears of the vaccine, and issues with access to care.  The main difference cited by 
parents as a reason not to vaccinate their sons was the fact that they thought their sons were at 
low risk for contracting HPV, and they thought vaccine was only given to protect their son’s 
future sexual partners.   
Both males and females need to receive thorough educational interventions from multiple 
sources.  If media advertisements are used as a trigger to stimulate HPV awareness the 
communication need to address the facts and promote HPV as an STD that affects both males 
and females alike.  Media advertisements also need to refer patients to their primary care 
providers to discuss their risks of HPV.  By doing this, it will increase the public’s confidence in 
the source, because the health care provider is an important facet of information for the patient 
when it comes to choosing whether or not to vaccinate.  Providing proper education will 
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minimize male and female patients’ knowledge deficits and fears.  In addition, all providers 
regardless of specialty should provide complete education on HPV, including where they can 
receive the vaccine.  This is extremely important, because the provider’s underperformance of 
educating patients on the HPV vaccine may be a major cause of the shortfall in vaccine uptake.   
In order to increase the rates of HPV vaccine administration and meet the HP 2020 goal 
of completing the three injection series on 80% of females between the ages of 13 to 15 (Bartlett 
et al., 2011), recommendations need to be more clearly stated by the ACIP.  The vaccine has 
been proven beneficial for both males and females, and therefore should be recommended for 
both sexes.  By changing the guideline to recommend the vaccine for both sexes there would be 
an increase in HPV awareness across health care providers.  There are only a few states that have 
added the HPV vaccine to the required list of vaccines to be administered prior to entering sixth 
grade.  If the vaccination guideline was clarified, more states could standardize their school 




 The barriers to HPV vaccine administration in males has been identified as: lack of 
education, perceived fears, and inaccessibility.  Identifying the barriers inhibiting males from 
receiving the HPV vaccine is the first step in breaking through the obstacles to increase vaccine 
uptake.  As stated previously, there are minimal studies available that focus on males receiving 
the HPV vaccine.  The literature reveals more research focusing on HPV in males is necessary.  
Additionally, more formal research studies are required in order to influence changes on 
evidence based practice and to improve guidelines.  Currently the Healthy People 2020 goals are 
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not well defined and are under development.  The vague goals include: to “vaccinate 80% of 
girls between ages 13 and 15, reduce the proportion of females with HPV types 6 & 11, reduce 
proportion of females with HPV types 16 & 18, and reduce the proportion of females with other 
HPV types”  (U.S. Department, 2012).  Only one of these goals state a specific measurable 
outcome, and currently all of the goals exclude males.   
 The lack of focus on males may be related to controversial issues with opponents 
of the vaccine arguing that the total rate of HPV diseases in males (anal, penile, and 
oropharyngeal cancers) are less than the rate of cervical cancer alone in women, and they 
continue to argue to be cost effective that the main focus of the HPV vaccine should remain 
solely on females (Castle, Cox, Palefsky, 2013).  Conversely, the immunization rates in females 
has remained low, and vaccinating only females will not protect homosexual males from 
contracting the virus from their partners (Castle et al., 2013) .   Controversy at hand, the ACIP 
needs to clarify the immunization recommendations of the quadrivalent vaccine to be included as 
a routine administration for males.  Currently the vaccine is listed as optional. 
By changing the status of the vaccine from optional to recommended, barriers to vaccine 
uptake in males will be easily overcome.  Providers will be better prepared to educate patients 
and parents on the vaccine with documented support from the ACIP.  Furthermore, by changing 
the vaccine to recommended more providers will be apt to carry the vaccine and more insurance 
providers will broaden plan coverage.  That being said, there would be a drastic improvement in 
access to the vaccine for patients.  Consequently, perceived fears of the vaccine will be 
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